What is the characteristic coagulation profile of hypothermic coagulopathy, in terms of prothrombin time (PT) and partial thromboplastin time (PTT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hypothermic Coagulopathy Characteristics

Hypothermic coagulopathy is characterized by prolonged prothrombin time (PT) and prolonged partial thromboplastin time (PTT) when measured at the patient's actual hypothermic temperature, though standard laboratory testing at 37°C will show normal or near-normal values—making answer (a) the correct response in clinical practice, despite the underlying pathophysiology causing both PT and PTT prolongation. 1, 2, 3

Laboratory Testing Paradox

The critical issue with hypothermic coagulopathy is the disparity between clinical coagulopathy and laboratory results 2:

  • Standard coagulation tests (PT and PTT) performed at 37°C will appear normal or near-normal, even when the patient has severe clinical coagulopathy 4, 1, 2
  • When PT and PTT are measured at hypothermic temperatures (≤35°C), both become significantly prolonged 4, 3
  • At 34°C, PT increases from 11.8 seconds to 12.9 seconds, and PTT increases from 36.0 seconds to 39.4 seconds 3
  • At 28°C, PT increases to 16.6 seconds and PTT increases to 57.2 seconds 3

Mechanism: Enzyme Dysfunction, Not Factor Depletion

Hypothermic coagulopathy does NOT involve depletion of clotting factors (eliminating answers d and e) 1, 2:

  • Hypothermia impairs the enzymatic activity of normally present coagulation factors, not their quantity 4, 1
  • Each 1°C drop in temperature causes approximately 10% reduction in coagulation factor function 4, 1
  • Platelet function becomes impaired between 33-37°C 4, 1
  • Below 33°C, thrombin activity, glycoprotein Ib-IX complex, and platelet aggregation are inhibited 4, 1

Clinical Implications

The appropriate treatment is rewarming, not administration of clotting factors or fresh frozen plasma 1, 2:

  • Hypothermia-induced coagulopathy is completely reversible with rewarming to 37°C 4, 1
  • Administering clotting factors is ineffective because the factors are already present but non-functional due to temperature 2
  • Rewarming strategies include removing wet clothing, forced air warming, warmed IV fluids, and in severe cases, extracorporeal rewarming 4, 1

Common Pitfall

Do not rely on standard PT/PTT results performed at 37°C to rule out coagulopathy in hypothermic patients 4, 1, 2, 3:

  • These tests will underestimate or completely miss the coagulopathy 4, 5
  • Clinical bleeding may be severe despite "normal" laboratory values 2, 6
  • Thromboelastography (TEG) and bleeding time are better predictors of actual coagulopathic bleeding than PT in hypothermic patients 6

Synergistic Effects

Hypothermia combined with acidosis creates a synergistic impairment of coagulation that is worse than either condition alone 4, 1:

  • Patients with the "lethal triad" (hypothermia, acidosis, and coagulopathy) have extremely poor outcomes 4, 1
  • One 8-year study found zero survivors among patients with all three conditions 4

References

Guideline

Hypothermic Coagulopathy Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Effect of hypothermia on the coagulation cascade.

Critical care medicine, 1992

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.